C4 Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $58,809 | $55,499 |
| Marketable securities, current | 133,075 | 189,405 |
| Accounts receivable | 6,542 | 3,102 |
| Prepaid expenses and other current assets | 8,438 | 9,761 |
| Total current assets | 206,864 | 257,767 |
| Marketable securities, non-current | 7,875 | 22,359 |
| Property and equipment, net | 5,134 | 5,842 |
| Right-of-use asset | 41,961 | 57,536 |
| Restricted cash | 3,443 | 3,443 |
| Other assets | 211 | 2,655 |
| Total assets | $265,488 | $349,602 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,333 | $1,328 |
| Accrued expenses and other current liabilities | 11,270 | 19,363 |
| Deferred revenue, current | 17,126 | 18,712 |
| Operating lease liability, current | 6,216 | 5,774 |
| Total current liabilities | 35,945 | 45,177 |
| Deferred revenue, net of current | 19,888 | 28,457 |
| Operating lease liability, net of current | 55,247 | 59,982 |
| Total liabilities | 111,080 | 133,616 |
| Commitments and contingencies (see Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, par value of $0.0001 per share; 300,000,000 and 150,000,000 shares authorized as of September 30, 2025, and December 31, 2024, respectively, and 74,174,515 and 70,625,899 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 7 | 7 |
| Additional paid-in capital | 872,521 | 849,625 |
| Accumulated other comprehensive income | 87 | 53 |
| Accumulated deficit | (718,207) | (633,699) |
| Total stockholders’ equity | 154,408 | 215,986 |
| Total liabilities and stockholders’ equity | $265,488 | $349,602 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.